Monopar Therapeutics (MNPR) EBT (2017 - 2019)
Historic EBT for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to -$1.2 million.
- Monopar Therapeutics' EBT fell 3222.7% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.3 million, marking a year-over-year decrease of 3688.5%. This contributed to the annual value of -$4.3 million for FY2019, which is 3104.1% down from last year.
- Per Monopar Therapeutics' latest filing, its EBT stood at -$1.2 million for Q4 2019, which was down 3222.7% from -$759448.0 recorded in Q3 2019.
- In the past 5 years, Monopar Therapeutics' EBT registered a high of -$373839.0 during Q1 2017, and its lowest value of -$14.9 million during Q3 2017.
- Its 3-year average for EBT is -$2.0 million, with a median of -$828354.0 in 2018.
- Examining YoY changes over the last 5 years, Monopar Therapeutics' EBT showed a top increase of 9551.92% in 2018 and a maximum decrease of 14001.24% in 2018.
- Monopar Therapeutics' EBT (Quarter) stood at -$736800.0 in 2017, then fell by 25.73% to -$926358.0 in 2018, then tumbled by 32.23% to -$1.2 million in 2019.
- Its EBT stands at -$1.2 million for Q4 2019, versus -$759448.0 for Q3 2019 and -$932109.0 for Q2 2019.